Results 51 to 60 of about 77,701 (209)

Differential renal effects of candesartan at high-and ultra-high doses in diabetic mice: potential role of  ACE2/AT2R/Mas [PDF]

, 2016
High doses of Ang II receptor (AT1R) blockers (ARBs) are renoprotective in diabetes. Underlying mechanisms remain unclear. We evaluated whether high/ultra-high doses of candesartan (ARB) up-regulate angiotensin-converting enzyme 2 (ACE2)/Ang II type 2 ...
Antunes, Tayze, Briones, Ana M., Burns, Kevin, Callera, Glaucia, Correa, Jose, Gutsol, Alexey, He, Ying, Montezano, Augusto C., Moorman, Danielle, Nguyen Dinh Cat, Aurelie, Touyz, Rhian M.   +10 more
core   +1 more source

Angiotensin II type 1 receptor blockers prevent aortic arterial stiffness in elderly patients with hypertension

Clinical and Experimental Hypertension, 2019
Backgrounds and aims: Increased arterial stiffness may increase cardiovascular morbidity and mortality. Angiotensin II type 1 receptor blockers (ARBs) are potentially useful in controlling the central blood pressure and arterial stiffness in mild to ...
Mo-Li Zhu, Rui-Li Sun, He-Yun Zhang, Fan-Rong Zhao, Guo-Pin Pan, Chong Zhang, Ping Song, Peng Li, Jian Xu, Shuangxi Wang, Ya-Ling Yin   +10 more
doaj   +1 more source

Pharmacist intervention in primary care to improve outcomes in patients with left ventricular systolic dysfunction [PDF]

, 2011
<b>Background</b> Meta-analysis of small trials suggests that pharmacist-led collaborative review and revision of medical treatment may improve outcomes in heart failure.<p></p> <b>Methods and results</b> We studied
Forsyth, P., Greenlaw, N., Jhund, P.S., Lowrie, R., Mair, F.S., McConnachie, A., McMurray, J.J.V., Rae, B.   +7 more
core   +1 more source

Angiotensin II type 1 receptor blocker inhibits arterial calcification in a pre-clinical model [PDF]

Cardiovascular Research, 2010
Arterial calcification is a common complication of several disorders and is a strong predictor of mortality. The mechanism underlying arterial calcification is not fully understood and as such, no pharmaceutical therapies are currently available which impede its progression.
Zachary B, Armstrong, Derek R, Boughner, Maria, Drangova, Kem A, Rogers   +3 more
openaire   +2 more sources

Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF) [PDF]

, 2014
Aim<p></p> To describe the baseline characteristics and treatment of the patients randomized in the PARADIGM-HF (Prospective comparison of ARNi with ACEi to Determine Impact on Global Mortality and morbidity in Heart Failure) trial, testing ...
Adel R. Rizkala, Akshay S Desai, Jean L. Rouleau, Jianjian Gong, John J. V. McMurray, Karl Swedberg, Martin Lefkowitz, Michael R. Zile, Milton Packer, null null, Scott D. Solomon, Victor C. Shi   +11 more
core   +3 more sources

Efficacy of Combined Bevacizumab and Angiotensin-Converting Enzyme Inhibitors or Angiotensin II type 1 Receptor Blockers in Metastatic Colorectal Cancer Patients [PDF]

Middle East Journal of Cancer
Background: Bevacizumab, used in the treatment of metastatic colorectal cancer (mCRC), has an angiogenesis inhibitory effect. Angiotensin converting enzyme inhibitors (ACEi) and angiotensin II type 1 receptor blockers (ARBs) used in the treatment of ...
Ali Kaan Güren, Nargiz Majidova, İclal Çakır, Nadiye Sever, Erkam Kocaaslan, Pınar Erel, Yeşim Ağyol, Abdussamed Çelebi, Rukiye Arıkan, Selver Işık, Murat Sarı, Özlem Ercelep, İbrahim Vedat Bayoğlu, Osman Köstek   +13 more
doaj   +1 more source

Factors associated with the progression of mesangial lesions in IgA nephropathy: A comparative analysis of renal re-biopsies

Frontiers in Endocrinology, 2022
ObjectivesIgA nephropathy (IgAN) is the most common primary glomerular disease, and is the leading cause of chronic renal failure. Because mesangial lesions are the main pathological changes seen in IgAN, we investigated factors associated with the ...
Yetong Li, Shimin Jiang, Hongmei Gao, Yue Yang, Xiaorong Liu, Wenge Li   +5 more
doaj   +1 more source

Clinical Comparative Trials of Angiotensin II Type 1 (AT 1 )-Receptor Blockers

Blood Pressure, 2001
Three characteristics of antihypertensive medication are pivotal in therapy for a patient with hypertension: potency and efficacy, duration of action, and the incidence of side-effects. The relatively new class of AT1-receptor blockers all display placebo-like tolerability and, as a class, their antihypertensive efficacy compares well with other ...
openaire   +2 more sources

Assessment and Management of Hypertension among Patients on Peritoneal Dialysis [PDF]

, 2019
Approximately 7%-10% of patients with ESKD worldwide undergo peritoneal dialysis (PD) as kidney replacement therapy. The continuous nature of this dialytic modality and the absence of acute shifts in pressure and volume parameters is an important ...
Agarwal, Rajiv, Georgianos, Panagiotis I., Liakopoulos, Vassilios, Vaios, Vasilios   +3 more
core   +1 more source

Angiotensin II inhibitor facilitates epidermal wound regeneration in diabetic mice

Frontiers in Physiology, 2015
Tissue regeneration and wound healing are severely impaired in diabetes and are associated with poor circulation and dysfunctional blood vessels. Angiotensin II inhibitors are anti-hypertensive drugs used in clinical practice to regulate blood pressure ...
Maria eKamber, Maria eKamber, Vasilis ePapalazarou, Georgia eRouni, Evagelia ePapageorgopoulou, Apostolos ePapalois, Vassiliki eKostourou   +6 more
doaj   +1 more source